Login / Signup

Blinding and bias in a hypnotic clinical trial.

William Vaughn McCallRuth M BencaMeredith E RumbleAndrew D Krystal
Published in: Human psychopharmacology (2020)
"Best guesses" of all parties were not different from chance, suggesting that the blind was maintained and that assessment bias was minimized in this RCT of zolpidem ER versus placebo. Our results may not apply to other hypnotics or other RCT designs.
Keyphrases
  • clinical trial
  • double blind
  • phase iii
  • phase ii
  • open label
  • estrogen receptor
  • study protocol
  • endoplasmic reticulum
  • breast cancer cells
  • randomized controlled trial
  • clinical evaluation